PHAXIAM Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
PHAXIAM Therapeutics has a total shareholder equity of €25.6M and total debt of €13.3M, which brings its debt-to-equity ratio to 51.8%. Its total assets and total liabilities are €51.3M and €25.7M respectively.
Key information
51.8%
Debt to equity ratio
€13.27m
Debt
| Interest coverage ratio | n/a |
| Cash | €10.47m |
| Equity | €25.61m |
| Total liabilities | €25.70m |
| Total assets | €51.31m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 2E40's short term assets (€16.2M) exceed its short term liabilities (€15.3M).
Long Term Liabilities: 2E40's short term assets (€16.2M) exceed its long term liabilities (€10.4M).
Debt to Equity History and Analysis
Debt Level: 2E40's net debt to equity ratio (10.9%) is considered satisfactory.
Reducing Debt: 2E40's debt to equity ratio has increased from 1.4% to 51.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if 2E40 has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 2E40 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.